Pharmacological modulation of 2-methyl-carbamate-PAF induced rat paw oedema

J Pharm Pharmacol. 1990 Mar;42(3):203-4. doi: 10.1111/j.2042-7158.1990.tb05388.x.

Abstract

Intraplantar injections of 2-methyl-carbamate-PAF (2-MC) (0.125-16.0 micrograms/paw) into the rat paw were followed by a bell-shaped dose response curve for inflammatory oedema, with an ascending phase at 0.125-2.0 micrograms/paw, and a descending phase at 4.0-16.0 micrograms/paw. The inflammatory response to 2-MC was partially inhibited by pre-treatment with aspirin (200 mg kg-1), NDGA (100 mg kg-1), dexamethasone (0.1 mg kg-1), verapamil (50 mg kg-1) and by a specific PAF antagonist BN 52021 (5-10 mg kg-1). The cyclo-oxygenase inhibitors indomethacin (2 mg kg-1) and piroxicam (1.8 mg kg-1) as well as antihistamine meclizine (40 mg kg-1) and ranitidine (50 mg kg-1) failed to block the oedematogenic response to 2-MC. Our data suggest that 2-MC induced rat paw oedema is mediated by PAF-acether receptors and is partially dependent on arachidonate lipoxygenase pathway and extracellular Ca2+.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Carbamates / pharmacology*
  • Diterpenes*
  • Edema / chemically induced
  • Edema / drug therapy*
  • Female
  • Ginkgolides
  • Lactones / pharmacology
  • Male
  • Platelet Activating Factor / pharmacology*
  • Rats
  • Rats, Inbred Strains

Substances

  • 2-methyl carbamate-platelet activating factor
  • Anti-Inflammatory Agents, Non-Steroidal
  • Carbamates
  • Diterpenes
  • Ginkgolides
  • Lactones
  • Platelet Activating Factor
  • ginkgolide B